Patients with colorectal cancer with high expression of circulating exosomal miR-27a or miR-130a underwent poorer prognosis.<b>Conclusions:</b> We identified a circulating exosomal miRNAs panel for the detection of colorectal cancer.<b>Impact:</b> The exosomal miR-27a and miR-130a panel in plasma may act as a noninvasive biomarker for early detection and predicting prognosis of colorectal cancer.
The overexpression of miR-27a in the human colorectal cancer cell line HCT-116<sup>+/+</sup> resulted in the decreased expression of the endogenous p53 protein levels.
Therefore, miR-27a could be a useful biomarker for monitoring colorectal cancer development and progression, and also could have a therapeutic potential by targeting SGPP1, Smad2 and STAT3 for colorectal cancer therapy.
The FCS method had a significant advantage over miRNA differential expression analysis when identifying cancer-related miRNAs with a fine regulatory mechanism, such as miR-27a in colorectal cancer.